SAFETY OF LONG-TERM TREATMENT WITH LURASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR DEPRESSION: WEEK 28 RESULTS OF A TWO-YEAR OPEN-LABEL EXTENSION STUDY

被引：2
|
作者：
Chang, Kiki [1 ]
DelBello, Melissa P. [2 ]
Goldman, Robert [3 ]
Tocco, Michael [3 ]
Pikalov, Andrei A. [3 ]
Cucchiaro, Josephine [3 ]
Loebel, Antony [3 ]
机构：
[1] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[2] Univ Cincinnati, Cincinnati, OH 45221 USA
[3] Sunov Pharmaceut Inc, Ft Lee, NJ USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY | 2017年 / 56卷 / 10期
关键词：
D O I：
10.1016/j.jaac.2017.09.048
中图分类号：
B844 [发展心理学（人类心理学）];
学科分类号：
040202 ;
摘要：
1.34
引用
收藏
页码：S163 / S163
页数：1
相关论文
共 50 条
  • [1] EFFECTIVENESS OF LONG-TERM TREATMENT WITH LURASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR DEPRESSION: WEEK 28 RESULTS OF A TWO-YEAR OPEN-LABEL EXTENSION STUDY
    Chang, Kiki
    DelBello, Melissa P.
    Goldman, Robert
    Tocco, Michael
    Pikalov, Andrei A.
    Cucchiaro, Josephine
    Loebel, Antony
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2017, 56 (10): : S266 - S267
  • [2] Safety of long-term treatment with lurasidone in children and adolescents with bipolar depression: week 28 results of a 2-year open-label extension study
    Chang, K.
    DelBello, M.
    Goldman, R.
    Tocco, M.
    Pikalov, A.
    Deng, L.
    Cucchiaro, J.
    Loebel, A.
    [J]. BIPOLAR DISORDERS, 2018, 20 : 66 - 66
  • [3] Effectiveness of long-term treatment with lurasidone in children and adolescents with bipolar depression: week 28 results of a 2-year open-label extension study
    Chang, K.
    DelBello, M.
    Goldman, R.
    Tocco, M.
    Pikalov, A.
    Deng, L.
    Cucchiaro, J.
    Loebel, A.
    [J]. BIPOLAR DISORDERS, 2018, 20 : 65 - 65
  • [4] EFFICACY AND SAFETY OF LURASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR DEPRESSION: INTERIM ANALYSIS OF A TWO-YEAR OPEN-LABEL EXTENSION STUDY
    Goldman, Robert S.
    DelBello, Melissa P.
    Tocco, Michael
    Pikalov, Andrei A.
    Deng, Ling
    Loebel, Antony
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2018, 57 (10): : S137 - S137
  • [5] SAFETY OF LONG-TERM TREATMENT WITH LURASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR DEPRESSION: INTERIM ANALYSIS OF A 2-YEAR OPEN-LABEL EXTENSION STUDY
    DelBello, M. P.
    Goldman, R.
    Tocco, M.
    Pikalov, A.
    Deng, L.
    Cucchiaro, J.
    Loebel, A.
    Coghill, D.
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2019, 53 : 144 - 144
  • [6] Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study
    Ishigooka, Jun
    Kato, Tadafumi
    Miyajima, Mari
    Watabe, Kei
    Masuda, Takahiro
    Hagi, Katsuhiko
    Higuchi, Teruhiko
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2021, 281 : 160 - 167
  • [7] Safety and effectiveness of long-term treatment with lurasidone in children and adolescents with bipolar depression: Interim analysis of a 2-year open-label extension study
    DelBello, M. P.
    Goldman, R.
    Tocco, M.
    Pikalov, A.
    Deng, L.
    Loebel, A.
    [J]. BIPOLAR DISORDERS, 2019, 21 : 133 - 133
  • [8] EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: RESULTS OF A TWO-YEAR OPEN-LABEL EXTENSION STUDY
    Goldman, Robert S.
    Tocco, Michael
    Pikalov, Andrei A.
    Deng, Ling
    Loebel, Antony
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2018, 57 (10): : S160 - S160
  • [9] EFFICACY OF LONG-TERM TREATMENT WITH LURASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR DEPRESSION: INTERIM ANALYSIS OF A 2-YEAR OPEN-LABEL EXTENSION STUDY
    DelBello, M. P.
    Goldman, R.
    Tocco, M.
    Pikalov, A.
    Deng, L.
    Cucchiaro, J.
    Loebel, A.
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2019, 53 : 143 - 144
  • [10] Efficacy and safety of lurasidone in children and adolescents with bipolar depression: Results from a 2-year open-label extension study
    DelBello, M. P.
    Goldman, R.
    Tocco, M.
    Pikalov, A.
    Deng, L.
    Loebel, A.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S236 - S236
12345